Modified DCF (mDCF) regimen seems to be as effective as original DCF in advanced gastric cancer (AGC).
作者： Serkan Keskin , I Yıldız , F Sen , F Aydogan , Leyla Kilic
DOI: 10.1007/S12094-012-0942-8
关键词: Surgery 、 Regimen 、 Advanced gastric cancer 、 Schedule 、 Adverse effect 、 Medicine 、 Internal medicine 、 Tolerability 、 MEDLINE 、 Retrospective cohort study 、 Docetaxel 、 Oncology
摘要: Purpose The aim of this retrospective study (from January 2007 to December 2011) was investigate the efficacy and tolerability mDCF schedule for chemotherapy-naive AGC patients.
unirioja.es
springer.com
sci-hub.se 参考文章(24)
Rodolfo Passalacqua, Sebastiano Buti, Gianluca Tomasello, Federica Negri, Matteo Brighenti, Silvia Lazzarelli, Gianvito Donati, Rodrigo Kraft Rovere, Matteo Dalla Chiesa, Antonio Brunelli, Massimo Buononato, Mario Martinotti, Dose-dense chemotherapy in metastatic gastric cancer with a modified docetaxel-cisplatin-5-fluorouracil regimen Tumori. ,vol. 96, pp. 48- 53 ,(2010) , 10.1700/479.5650
Michael J. Overman, Syed M. Kazmi, Jagriti Jhamb, E Lin, James C. Yao, James L. Abbruzzese, Linus Ho, Jaffer Ajani, Alexandria Phan, Weekly docetaxel, cisplatin, and 5‐fluorouracil as initial therapy for patients with advanced gastric and esophageal cancer Cancer. ,vol. 116, pp. 1446- 1453 ,(2010) , 10.1002/CNCR.24925
A Inal, MA Kaplan, M Kucukoner, A Isikdogan, None, Docetaxel and Cisplatin Plus Fluorouracil compared with Modified Docetaxel, Cisplatin, and 5-Fluorouracil as first-line therapy for advanced gastric cancer: a retrospective analysis of single institution. Neoplasma. ,vol. 59, pp. 233- 236 ,(2012) , 10.4149/NEO_2012_030
N C Tebbutt, , M M Cummins, T Sourjina, A Strickland, G Van Hazel, V Ganju, D Gibbs, M Stockler, V Gebski, J Zalcberg, Randomised, non-comparative phase II study of weekly docetaxel with cisplatin and 5-fluorouracil or with capecitabine in oesophagogastric cancer: the AGITG ATTAX trial British Journal of Cancer. ,vol. 102, pp. 475- 481 ,(2010) , 10.1038/SJ.BJC.6605522
Sook Ryun Park, Jong Ho Chun, Young Woo Kim, Jun Ho Lee, Il Ju Choi, Chan Gyoo Kim, Jong Seok Lee, Jae-Moon Bae, Hark Kyun Kim, Phase II study of low-dose docetaxel/fluorouracil/cisplatin in metastatic gastric carcinoma. American Journal of Clinical Oncology. ,vol. 28, pp. 433- 438 ,(2005) , 10.1097/01.COC.0000162424.69631.79
S Pyrhönen, T Kuitunen, P Nyandoto, M Kouri, Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer. British Journal of Cancer. ,vol. 71, pp. 587- 591 ,(1995) , 10.1038/BJC.1995.114
Jaffer A. Ajani, Miguel B. Fodor, Sergei A. Tjulandin, Vladimir M. Moiseyenko, Yee Chao, Sebastiao Cabral Filho, Alejandro Majlis, Sylvie Assadourian, Eric Van Cutsem, Phase II Multi-Institutional Randomized Trial of Docetaxel Plus Cisplatin With or Without Fluorouracil in Patients With Untreated, Advanced Gastric, or Gastroesophageal Adenocarcinoma Journal of Clinical Oncology. ,vol. 23, pp. 5660- 5667 ,(2005) , 10.1200/JCO.2005.17.376
Masahiko Nishiyama, Satoru Wada, Docetaxel: its role in current and future treatments for advanced gastric cancer. Gastric Cancer. ,vol. 12, pp. 132- 141 ,(2009) , 10.1007/S10120-009-0521-Z
P Bohanes, DS Courvoisier, TV Perneger, P Morel, O Huber, AD Roth, Survival predictors for second-line chemotherapy in Caucasian patients with metastatic gastric cancer Swiss Medical Weekly. ,vol. 141, ,(2011) , 10.4414/SMW.2011.13249
Sameer H. Patel, David A. Kooby, Gastric adenocarcinoma surgery and adjuvant therapy. Surgical Clinics of North America. ,vol. 91, pp. 1039- 1077 ,(2011) , 10.1016/J.SUC.2011.06.009